USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated